Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region

被引:15
作者
Jazieh, Abdul Rahman [1 ]
Jaafar, Iasan [2 ]
Jaloudi, Mohammed [2 ]
Mustafa, Rasha Saleh [3 ]
Rasul, Kakil [4 ]
Zekri, Jamal [5 ]
Bamefleh, Hanaa [1 ]
Gasmelseed, Ahmed [1 ]
机构
[1] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Natl Guard Hlth Affairs, Dept Oncol, Riyadh 11426, Saudi Arabia
[2] Tawam Hosp, Dept Oncol, Al Ain 15258, U Arab Emirates
[3] King Fand Med City, Riyadh 11525, Saudi Arabia
[4] Al Amal Hosp, Dept Oncol, Doha 3050, Qatar
[5] King Faisal Specialist & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia
关键词
non-small-cell lung cancer; epidermal growth factor receptor; Gulf region;
D O I
10.3892/mco.2015.644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to determine the prevalence of epidermal growth factor receptor mutations (EGFRmut) in the Gulf region (GR) and its correlation with demographic and clinical characteristics. A multisite retrospective study was conducted, including institutions from Saudi Arabia, the United Arab Emirates and Qatar. All consecutive patients with non-small-cell lung cancer tested for EGFRmut were eligible. Data collected included demographic information, disease characteristics and EGFR test results. Data on 230 patients were obtained. The median age of the patients was 61 years (range, 26-87 years); 169 patients (69.83%) were male and 204 (88.7%) were Arab. The histological subtype was adenocarcinoma in 191 (83.4%) and squamous cell carcinoma in 21 cases (9.17%). Overall, EGFRmut were detected in 66 patients (28.7%), with a prevalence of 32.46% in adenocarcinoma. No squamous cell carcinomas were found to harbor EGFRmut. The univariate and multivariate analyses revealed that female gender, non-smoking status and adenocarcinoma subtype were significant predictors for EGFRmut. There was no difference between Arabs and non-Arabs. In conclusion, to the best of our knowledge, this is the first multisite study to report the prevalence of EGFRmut in the GR population, which was found to be higher compared with that in Western, but lower compared with that in Far Eastern populations. Studies evaluating the efficacy of targeted therapy in this population are underway.
引用
收藏
页码:1371 / 1374
页数:4
相关论文
共 12 条
[1]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937
[2]   Drug therapy: EGFR antagonists in cancer treatment [J].
Ciardiello, Fortunato ;
Tortora, Giampaolo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174
[3]   United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets [J].
Cohen, MH ;
Williams, GA ;
Sridhara, R ;
Chen, G ;
McGuinn, WD ;
Morse, D ;
Abraham, S ;
Rahman, A ;
Liang, CY ;
Lostritto, R ;
Baird, A ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1212-1218
[4]   Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma [J].
Errihani, Hassan ;
Inrhaoun, Hanane ;
Boukir, Anouar ;
Kettani, Fouad ;
Gamra, Lamia ;
Mestari, Amina ;
Jabri, Lamia ;
Bensouda, Youssef ;
Mrabti, Hind ;
Elghissassi, Ibrahim .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (09) :1212-1214
[5]   Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population [J].
Fakhruddin, Najla ;
Mahfouz, Rami ;
Farhat, Fadi ;
Tfayli, Arafat ;
Abdelkhalik, Rabab ;
Jabbour, Mark ;
Yehia, Lamis ;
Mahfoud, Ziyad ;
Zaatari, Ghazi .
ONCOLOGY REPORTS, 2014, 32 (05) :2223-2229
[6]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[7]   EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].
Kobayashi, S ;
Boggon, TJ ;
Dayaram, T ;
Janne, PA ;
Kocher, O ;
Meyerson, M ;
Johnson, BE ;
Eck, MJ ;
Tenen, DG ;
Halmos, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792
[8]   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].
Kris, MG ;
Natale, RB ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Kelly, K ;
Spiridonidis, H ;
Sandler, A ;
Albain, KS ;
Cella, D ;
Wolf, MK ;
Averbuch, SD ;
Ochs, JJ ;
Kay, AC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158
[9]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[10]   A translational view of the molecular pathogenesis of lung cancer [J].
Sato, Mitsuo ;
Shames, David S. ;
Gazdar, Adi F. ;
Minna, John D. .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) :327-343